|
|
Suppliers for
Telavancin hydrochloride
|
Properties | CAS |
560130-42-9 | Formula |
C80H106Cl2N11O27P.HCl |
|
3 Registered suppliers
Molecular Formula: C80H107Cl3N11O27P Molecular Weight: 1792.095841
Molecular Formula: C80H107Cl3N11O27P Molecular Weight: 1792.095841
Description : Telavancin hydrochloride, a derivative of vancomycin, is a potent medication used to combat an array of bacterial infections. These infections include, but are not limited to, skin and soft tissue infections, bloodstream infections caused by Staphylococcus aureus, and Streptococcus pyogenes. Its mode of action is to repress the synthesis of bacterial cell walls. Its efficacy against methicillin-resistant organisms makes it a highly effective option against bacterial infections in clinical settings. - Molecular Weight :1792.096
Molecular Formula : C80H106Cl2N11O27P·HCl Canonical SMILES : CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C.Cl InChI : InChI=1S/C80H106Cl2N11O27P.ClH/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39;/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114);1H/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-;/m0./s1 InChIKey : GSSIWSIRBWAZHG-ACOPVEIWSA-N Synonyms : Telavancin Hydrochloride; 560130-42-9; Telavancin HCl; Vibativ; UNII-0701472ZG0
More details are to be found here
|
|
|
Privileged suppliers
Last update 2024-05-10
|